卵巢癌的治疗药物研究进展  

Research progress on drugs in treatment of ovarian cancer

作　　者：田红[1] 于鹏[1] 吴小茗 田苗[1] 肖桂芝[1] 沈雪砚[1] 陈常青[1] 

机构地区：[1]天津药物研究院有限公司医药信息中心,天津300193 [2]吉林康乃尔药业有限公司,吉林吉林132013

出　　处：《现代药物与临床》2015年第1期103-107,共5页Drugs & Clinic

摘　　要：卵巢癌是女性生殖器官常见的恶性肿瘤之一,其死亡率居妇科恶性肿瘤首位,且发病率逐年增加。全球新批准并上市的治疗卵巢癌的药物有贝伐单抗、曲贝替定、人参皂苷以及一些新制剂,处于研发后期的抗卵巢癌药物有奥拉帕尼、西地尼布、nintedanib、trebananib以及一些抗卵巢癌药的新剂型品种等。对近年来上市和处于研发后期的卵巢癌的治疗药物进行了详细介绍,同时对抗卵巢癌药的未来发展方向进行了展望,以期为抗卵巢癌药物的研发提供参考。Ovarian cancer is one of the most common gynecological malignant tumors in women, and its mortality heads the list. The incidence rate has increased year by year. Drugs in treatment of ovarian cancer approved for sale include bevacizumab, trabectedin, ginsenoside, and some new formulations; Ovarian cancer drugs under development include olaparib, cediranib, nintedanib, trebananib, and some new formulations. Ovarian cancer drugs（launched and R ＆D） are introduced, and the future development direction of ovarian cancer drugs is prospected in this paper, in order to provide a basis for ovarian cancer drugs.

关 键 词：治疗药物 卵巢癌 贝伐单抗 奥拉帕尼 西地尼布 

分 类 号：R979.1[医药卫生—药品]